Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

November 30, 2018

First Patient Dosed in Phase 1b Trial of Sitravatinib-Tislelizumab Combo for Advanced Solid Tumors

News

A Phase 1b clinical trial studying a combination of Mirati Therapeutics‘ small molecule inhibitor sitravatinib and BeiGene‘s immune checkpoint inhibitor tislelizumab has begun dosing patients. The open-label, multicenter trial (NCT03666143), expected to ... Read more

November 9, 2018

Zejula Leads to Fewer Side Effects Than Previously Reported, Real-world Study Suggests

News

Ovarian cancer patients who receive Zejula (niraparib) after responding to platinum-based chemotherapy experience fewer adverse effects in a real-world setting than was reported in a Phase 3 clinical trial, a ... Read more

October 22, 2018

First Patient Dosed in Phase 1 Trial of MCY-M11 in Ovarian Cancer, Peritoneal Mesothelioma

News

MaxCyte has begun dosing participants in a Phase 1 trial to assess its lead CAR T-cell therapy, MCY-M11, for the treatment of advanced ovarian cancer and peritoneal mesothelioma patients who ... Read more

September 24, 2018

Adding Yervoy to Opdivo Increases Responses in Some Ovarian Cancer Patients, Phase 2 Study Shows

News

A combination of Opdivo (nivolumab) and Yervoy (ipilimumab) leads to better response rates in patients with persistent or recurrent ovarian cancer than Opdivo alone, a Phase 2 study shows. ... Read more

May 17, 2017

First Patient Dosed in Syros’ Phase 1 Trial for Ovarian, Other Solid Tumors

News

The first patient has been dosed in a Phase 1 trial assessing Syros Pharmaceuticals‘ investigative therapy SY-1365 in patients with advanced solid tumors, the company announced. The trial will ... Read more

May 15, 2017May 15, 2017

Potential Therapy, Niraparib, Available to Select Patients in Europe via Managed Access Program

News

Recurrent ovarian cancer patients in Europe with few or no treatment options may soon have access to an investigational therapy, niraparib, under a managed access program launched by Tesaro, the drug’s developer, and the British-based Clinigen Group. The European ... Read more

May 10, 2017May 10, 2017

First Patient Enrolled in Phase 1/2 Trial for Recurrent Ovarian Cancer

News

The first patient has been dosed in a Phase 1/2 trial assessing OncoQuest‘s anti-CA125 antibody oregovomab in combination with Opdivo (nivolumab) in women with recurrent ovarian cancer. The ORION-01 trial ... Read more

April 21, 2017April 21, 2017

CA4P Combo Treatment Shows Promise in Platinum-Resistant Ovarian Cancer Trial

News

An interim analysis from the Phase 2/3 clinical trial assessing Mateon Therapeutics‘ CA4P suggests the drug therapy is safe and effective in platinum-resistant ovarian cancer patients, when used in ... Read more

April 19, 2017April 19, 2017

Precision Biologics’ New Antibody Targets Tumor Activity in Ovarian, Other Cancer Cells

News

Dallas-based Precision Biologics says its new antibody targets tumor cells expressing the NEO-201 neo-antigen, which are present in ovarian and gastrointestinal cancers. The company presented new preclinical data earlier this month at ... Read more

April 10, 2017

TTFields, Taxol Combo Shows Promise in Recurrent Ovarian Cancer Patients

News

Patients with recurrent ovarian cancer may greatly benefit from the addition of Tumor Treating Fields (TTFields), a method that uses electric fields to disrupt cell division, to Taxol (paclitaxel), according ... Read more

Pin It on Pinterest